|The Swedish University of Agricultural Sciences (SLU), Uppsala.
SLU, the Swedish University of Agricultural Sciences, is one of our partners for the development of a new generation of animal health vaccines using recombinant proteins. SLU is a world-class international university with research, education and environmental assessment within the sciences for sustainable life.
|Karolinska Institute, KI, Stockholm.
Karolinska Institutet, KI is one of our partners for the development of a new generation of animal health vaccines using recombinant proteins. KI is one of the world’s foremost medical universities including both research and education with a vision is to advance knowledge about life and strive towards better health for all.
|Moredun Scientific, Edinburgh, Skottland.
Our cooperating partner in the Eurostars-2 funded project for further development of a vaccine against infection of piglets caused by Streptococcus suis. Moredun Scientific is a contract research organisation specialising in animal health and biosafety testing of biopharmaceuticals.
|3P Biopharmaceuticals, Pamplona, Spain
3P Biopharmaceuticals is our partner for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine against strangles. The collaboration between the Companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.
|LIOF-Pharma (previosly Praxis Pharmaceutical), Spain
LIOF-Pharma in Spain provides final formulation, filling of vials and packaging of finished product.
|Novavax AB, Uppsala
Novavax have developed a patented technology that enhances the effect of vaccines (adjuvants). The technique is based on different immune-stimulating components, saponins, which are extracted from the tree Quillaja saponaria. Following purification the immune-stimulating components produce different complexes named iscomes. Iscomes are included in several authorised vaccines amongst one of which is a vaccine against horse influensa. Intervacc has an agreement with Novavax to use the iscome technology in its strangles vaccine.
|AWA Patent, Stockholm
|Cirio Law Firm, Stockholm
Audit and Financial advisory